PT93337A - Ensaio para o tratamento e doencas autoimunitarias - Google Patents

Ensaio para o tratamento e doencas autoimunitarias

Info

Publication number
PT93337A
PT93337A PT93337A PT9333790A PT93337A PT 93337 A PT93337 A PT 93337A PT 93337 A PT93337 A PT 93337A PT 9333790 A PT9333790 A PT 9333790A PT 93337 A PT93337 A PT 93337A
Authority
PT
Portugal
Prior art keywords
treatment
test
diseases
autoimmunity diseases
autoimmunity
Prior art date
Application number
PT93337A
Other languages
English (en)
Other versions
PT93337B (pt
Inventor
Kanianthara George Chandy
Michael Daniel Cahalan
Stephen Grissmer
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of PT93337A publication Critical patent/PT93337A/pt
Publication of PT93337B publication Critical patent/PT93337B/pt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/24Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT93337A 1989-03-06 1990-03-05 Ensaio para o tratamento e doencas autoimunitarias PT93337B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31949989A 1989-03-06 1989-03-06

Publications (2)

Publication Number Publication Date
PT93337A true PT93337A (pt) 1990-11-07
PT93337B PT93337B (pt) 1997-01-31

Family

ID=23242496

Family Applications (1)

Application Number Title Priority Date Filing Date
PT93337A PT93337B (pt) 1989-03-06 1990-03-05 Ensaio para o tratamento e doencas autoimunitarias

Country Status (10)

Country Link
EP (1) EP0463114B1 (pt)
JP (1) JPH04504173A (pt)
AT (1) ATE138196T1 (pt)
CA (1) CA2049007A1 (pt)
DE (1) DE69027025T2 (pt)
FI (1) FI914160A7 (pt)
IE (1) IE900786L (pt)
NO (1) NO913499L (pt)
PT (1) PT93337B (pt)
WO (1) WO1990010871A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69232722T2 (de) * 1991-08-23 2002-12-05 The Board Of Regents Of The University Of Nebraska, Lincoln Verfahren und zusammensetzungen für zelluläre reprogrammierung
WO1996010091A1 (en) * 1994-09-29 1996-04-04 Merck & Co., Inc. A high capacity screen for immunoregulants
GB9520411D0 (en) * 1995-10-06 1995-12-06 Wales College Of Medicine Method of testing
US6979547B2 (en) 1998-03-25 2005-12-27 Cornell Research Foundation, Inc. Methods for designing specific ion channel blockers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03503887A (ja) * 1988-02-03 1991-08-29 エクソウマ コーポレーション 自己免疫疾患に対する抗t細胞イムノトキシンの治療的使用
JPH03503164A (ja) * 1988-02-03 1991-07-18 エクソウマ コーポレーション 抗‐パンt‐細胞イムノトキシン組成物による免疫抑制

Also Published As

Publication number Publication date
CA2049007A1 (en) 1990-09-07
NO913499D0 (no) 1991-09-05
DE69027025D1 (de) 1996-06-20
FI914160A0 (fi) 1991-09-03
EP0463114A4 (en) 1992-01-22
EP0463114B1 (en) 1996-05-15
PT93337B (pt) 1997-01-31
IE900786L (en) 1990-09-06
EP0463114A1 (en) 1992-01-02
ATE138196T1 (de) 1996-06-15
DE69027025T2 (de) 1996-10-24
FI914160A7 (fi) 1991-09-03
JPH04504173A (ja) 1992-07-23
WO1990010871A1 (en) 1990-09-20
NO913499L (no) 1991-09-05

Similar Documents

Publication Publication Date Title
Lies et al. Relative T‐cell specificity of lymphocytotoxins from patients with systemic lupus erythematosus
NO179615C (no) Monoklonale antistoffer eller fragmenter derav som reagerer med kakektin, cellelinjer som produserer dem, prövesett som omfatter dem, samt anvendelse derav in vitro
ES2075050T3 (es) Peptidos que tienen actividad cooperadora de celulas t.
NO985468D0 (no) Antistoff og diagnostisk preparat omfattende dette
Golub The distribution of brain-associated ϑ antigen cross-reactive with mouse in the brain of other species
DE69014474D1 (de) Antikörper gegen TNF-Bindungsprotein I und deren F(ab)-Fragmente.
ES2128362T3 (es) Fragmentos de proteinas de prion.
HUP9903378A2 (hu) Az autoimmun betegségek immunterápiájában felhasználható autoantigének és ezekkel szerkezetileg rokon fehérjék
DK228190D0 (da) Rajgraespollenallergen
ATE244299T1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
ES499227A0 (es) Procedimiento para la determinacion de antigenos carcinoem- brionicos en el plasma humano
DE3853718D1 (de) Menschliche gamma, delta-t-zellen-antigen-rezeptor-polypeptide und nukleinsäuren.
FR2491334B1 (pt)
CA2070647A1 (en) Use of an anticoagulant as a diagnostic agent
ES2172287T4 (es) Metodos de deteccion y tratamiento de individuos con celulas anormales que expresan los antigenos peptidicos hla-a2/tirosinasa.
ES2072423T3 (es) Anticuerpo monoclonal e inmunoensayo para el factor beta xiia de coagulacion de la sangre.
ES2053712T3 (es) Un antigeno proteico reactivo y fragmentos del mismo.
ES2100960T3 (es) Estructura proteica de la toxina vegetal gelonina.
ES2065974T3 (es) Agente para ensayos inmunoquimicos que contiene polimeros con contenido de grupos carboxilo.
FI914160A0 (fi) Analysis och behandling av auto- immuniska sjukdomar.
PT837672E (pt) Preparacoes e metodos para o tratamento de doencas mediadas por celulas t
FR2642526B1 (fr) Utilisation de generateur de radicaux libres dans le domaine des dosages biologiques
WO1990007321A3 (en) Lymphocyte receptor homing sequences and their uses
ES2130629T3 (es) Compuestos peptidicos de proinsulina para detectar y tratar la diabetes tipo i.
ES2308850T3 (es) Anticuerpos para antigenos de celulas de langerhans de mamiferos y sus usos.

Legal Events

Date Code Title Description
FG3A Patent granted, date of granting

Effective date: 19961023

MM3A Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 19980430